Insider Selling: Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) COO Sells 65,902 Shares of Stock

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) COO Matthew Maxwell Donley sold 65,902 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total transaction of $527,216.00. Following the transaction, the chief operating officer now directly owns 739,456 shares in the company, valued at $5,915,648. This trade represents a 8.18 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Aurinia Pharmaceuticals Stock Performance

NASDAQ AUPH traded up $0.10 on Tuesday, hitting $8.08. 3,640,172 shares of the stock traded hands, compared to its average volume of 1,449,999. The business’s fifty day moving average is $8.13 and its two-hundred day moving average is $7.85. Aurinia Pharmaceuticals Inc. has a 12 month low of $4.71 and a 12 month high of $10.67. The firm has a market capitalization of $1.16 billion, a price-to-earnings ratio of -53.86 and a beta of 1.22. The company has a debt-to-equity ratio of 0.17, a quick ratio of 5.11 and a current ratio of 5.60.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. GF Fund Management CO. LTD. purchased a new position in shares of Aurinia Pharmaceuticals during the fourth quarter worth about $27,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its position in shares of Aurinia Pharmaceuticals by 21.9% during the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 363,674 shares of the biotechnology company’s stock valued at $3,266,000 after purchasing an additional 65,220 shares during the last quarter. Woodline Partners LP raised its stake in shares of Aurinia Pharmaceuticals by 69.7% during the fourth quarter. Woodline Partners LP now owns 849,477 shares of the biotechnology company’s stock worth $7,628,000 after acquiring an additional 348,983 shares in the last quarter. Vermillion & White Wealth Management Group LLC bought a new position in shares of Aurinia Pharmaceuticals during the 4th quarter valued at $31,000. Finally, Tang Capital Management LLC grew its holdings in shares of Aurinia Pharmaceuticals by 16.6% during the 4th quarter. Tang Capital Management LLC now owns 8,429,500 shares of the biotechnology company’s stock valued at $75,697,000 after purchasing an additional 1,200,000 shares during the last quarter. 36.83% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Wednesday, February 19th.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.